Abstract
Background: Breast carcinoma is a malignant disease that represents the most common
non-skin malignancy and a chief reason of cancer death in women. Large interest is growing in the
use of natural products for cancer treatment, especially with goal of suppression angiogenesis, tumor
cell growth, motility, as well as invasion and metastasis with low/no toxicity. It is evident
from recent patents on the anticancer properties of sesquiterpene lactones such as parthenolide.
Objective: In this study, using MDA-MB-231 cells of a human breast adenocarcinoma, the effects
of aguerin B, as a natural sesquiterpene lactone, has been evaluated, in terms of the expression of
metastatic-related genes (Pak-1, Rac-1 and HIF-1α).
Methods: Cytotoxicity of aguerin B was tested toward MDA-MB-231 breast tumor cells using
MTT. Scratch assay was accomplished to evaluate the tumor cell invasion. To understand the underlying
molecular basis, the mRNA expressions were evaluated by real time PCR.
Results: It was found that aguerin B significantly inhibited human breast cancer cell growth in
vitro (IC50 = 2μg/mL) and this effect was accompanied with a persuasive suppression on metastasis.
Our results showed that aguerin B in IC50 concentration down-regulated Rac-1, Pak-1, Hif-1α
and Zeb-1 transcriptional levels.
Conclusion: Taken together, this study demonstrated that aguerin B possessed potential anti-metastatic
effect, suggesting that it may consider as a potential multi target bio compound for treatment
of breast metastatic carcinoma.
Keywords:
Aguerin B, anticancer, breast metastatic carcinoma, patent, Rac-1, sesquiterpene lactone.
[8]
Guerra G. Poletto V, Biggiogera M, et al. Circulating endothelial progenitor cells from patients with renal cell carcinoma display aberrant VEGF regulation, reduced apoptosis and altered ultrastructure. Ital J Anat Embryol 2015; 120: 111.
[22]
Rhodes A. Method for the extraction of sesquiterpene lactones. US5384121, In: 1995.
[23]
Hsieh H-P, Hsu T-A, Hwang D-R. Treatment of hepatitis C virus infection with sesquiterpene lactones. . US20040229936, In: 2004.
[24]
Elsebai MF. Sesquiterpene lactones as potent and broad spectrum antiviral compounds against all genotypes of Hepatitis C Virus (HCV). . WO2016169573, In: 2016.
[25]
Grothe T, Roemer E, Wabnitz P. Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions US20130023586,. 2013.
[26]
Hwang DH, Fischer NH. Use of sesquiterpene lactones for treatment of severe inflammatory disorders. . US5905089, In: 1999.
[27]
Jean D. Cosmetic or medicinal composition containing sesquiterpene lactone or the like for treating hair-growth related disorders, and preparation method. US20040115289, In: 2004.
[28]
Gobrecht PLA, Fischer D. Parthenolide and its derivative for use in the treatment of axonal damage. US20190388388, In: 2019.
[29]
Myers CE, Trepel J, Sausville E, Samid D, Miller A, Curt G. Monoterpenes, sesquiterpenes and diterpenes as cancer therapy. US5602184 In: 1997.
[33]
He H, Zheng L, Sun YP, Zhang GW, Yue ZG. Steroidal saponins from Paris polyphylla suppress adhesion, migration and invasion of human lung cancer A549 cells via down-regulating MMP-2 and MMP-9. APJCP 2014; 15: 10911-6.